PuSH - Publication Server of Helmholtz Zentrum München

Gasser, M.* ; Boonsimma, P.* ; Netbaramee, W.* ; Wechapinan, T.* ; Srichomthomg, C.* ; Ittiwut, C.* ; Krenn, M.* ; Zimprich, F.* ; Milenkovic, I.* ; Abicht, A.* ; Biskup, S.* ; Roser, T.* ; Shotelersuk, V.* ; Tacke, M.* ; Kuersten, M.* ; Wagner, M. ; Borggraefe, I.* ; Suphapeetiporn, K.* ; von Stülpnagel, C.*

ATP1A3-related epilepsy: Report of seven cases and literature-based analysis of treatment response.

J. Clin. Neurosci. 72, 31-38 (2020)
DOI PMC
Open Access Green as soon as Postprint is submitted to ZB.
ATP1A3 related disease is a clinically heterogeneous condition currently classified as alternating hemiplegia of childhood, rapid-onset dystonia-parkinsonism and cerebellar ataxia, areflexia, pes cavus, optic atrophy, and sensorineural hearing loss. Recently, it has become apparent that a remarkably large subgroup is suffering from often difficult-to-treat epilepsy. The aim of the present study was to assess the prevalence and efficacy of commonly used anti-epileptic-drugs (AEDs) in patients with ATP1A3 related seizures. Therefore, we performed a retrospective study of patients in combination with a systematic literature-based review. Inclusion criteria were: verified ATP1A3 mutation, seizures and information about AED treatment. The literature review yielded records for 188 epileptic ATP1A3 patients. For 14/188 cases, information about anti-epileptic treatment was available. Combined with seven unpublished records of ATP1A3 patients, a sample size of 21 patients was reached. Most used AED were levetiracetam (n = 9), phenobarbital (n = 8), valproic acid (n = 7), and topiramate (n = 5). Seizure reduction was reported for 57% of patients (n = 12). No individual AEDs used (either alone or combined) had a success rate over 50%. There was no significant difference in the response rate between various AEDs. Ketogenic diet was effective in 2/4 patients. 43% of patients (n = 9) did not show any seizure relief. Even though Epilepsy is a significant clinical issue in ATP1A3 patients, only a minority of publications provide any information about patients' anti-epileptic treatment. The findings of treatment effectiveness in only 57% (or lower) of patients, and the non-existence of a clear first-line AED in ATP1A3 related epilepsy stresses the need for further research.
Altmetric
Additional Metrics?
Edit extra informations Login
Publication type Article: Journal article
Document type Scientific Article
Corresponding Author
Keywords Aed ; Atp1a3 ; Case Report ; Epilepsy ; Review ; Treatment
ISSN (print) / ISBN 0967-5868
e-ISSN 1532-2653
Quellenangaben Volume: 72, Issue: , Pages: 31-38 Article Number: , Supplement: ,
Publisher Elsevier
Non-patent literature Publications
Reviewing status Peer reviewed